On July 25, 2023, the Board of Directors of Homology Medicines, Inc. approved a reduction in the Company?s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company?s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.61 USD | +3.10% | +4.82% | +153.56% |
May. 09 | Q32 Bio Inc. Provides Corporate Update | CI |
Apr. 11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+153.56% | 331M | |
+3.95% | 111B | |
+11.45% | 105B | |
-12.55% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.67% | 16.96B | |
+3.11% | 13.7B | |
+37.02% | 12.45B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Approves Reduction in Workforce